Skip to main content

Fordyce Marshall's Form 4 filing

Vera Therapeutics, Inc.VERA · filed Nov 15, 2024

Accession no.
0001415889-24-026944
Filed
Nov 15, 2024
Trade date
Nov 13, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 18 non-derivative transactions and 6 derivative transactions. Open-market sales total $1.52M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Fordyce MarshallCIK 0001859453Director, Officer (PRESIDENT AND CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 13, 2024Class A Common StockMOption exerciseAcquired+12,218$2.90+$35,432.298,160Direct
Nov 13, 2024Class A Common StockSSaleDisposed−12,218$49.54F3−$605,279.7285,942Direct
Nov 13, 2024Class A Common StockMOption exerciseAcquired+3,307$2.90+$9,590.389,249Direct
Nov 13, 2024Class A Common StockSSaleDisposed−3,307$50.28F4−$166,275.9685,942Direct
Nov 13, 2024Class A Common StockMOption exerciseAcquired+100$2.90+$29086,042Direct
Nov 13, 2024Class A Common StockSSaleDisposed−100$51.20−$5,12085,942Direct
Nov 13, 2024Class A Common StockMOption exerciseAcquired+1,565$2.90+$4,538.587,507Direct
Nov 13, 2024Class A Common StockSSaleDisposed−1,565$49.59F5−$77,608.3585,942Direct
Nov 13, 2024Class A Common StockMOption exerciseAcquired+310$2.90+$89986,252Direct
Nov 13, 2024Class A Common StockSSaleDisposed−310$50.35F6−$15,608.585,942Direct
Nov 13, 2024Class A Common StockMOption exerciseAcquired+1,875$2.90+$5,437.587,817Direct
Nov 13, 2024Class A Common StockSSaleDisposed−1,875$49.57F7−$92,943.7585,942Direct
Nov 13, 2024Class A Common StockMOption exerciseAcquired+1,875$2.90+$5,437.587,817Direct
Nov 13, 2024Class A Common StockSSaleDisposed−1,875$49.52F7−$92,85085,942Direct
Nov 13, 2024Class A Common StockMOption exerciseAcquired+1,875$2.90+$5,437.587,817Direct
Nov 13, 2024Class A Common StockSSaleDisposed−1,875$49.50F7−$92,812.585,942Direct
Nov 13, 2024Class A Common StockMOption exerciseAcquired+7,500$2.90+$21,75093,442Direct
Nov 13, 2024Class A Common StockSSaleDisposed−7,500$49.00−$367,50085,942Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 13, 2024Class A Common StockMOption exerciseDisposed−15,625$0.00$0753,587Direct
Nov 13, 2024Class A Common StockMOption exerciseDisposed−1,875$0.00$0751,712Direct
Nov 13, 2024Class A Common StockMOption exerciseDisposed−1,875$0.00$0749,837Direct
Nov 13, 2024Class A Common StockMOption exerciseDisposed−1,875$0.00$0747,962Direct
Nov 13, 2024Class A Common StockMOption exerciseDisposed−1,875$0.00$0746,087Direct
Nov 13, 2024Class A Common StockMOption exerciseDisposed−7,500$0.00$0738,587Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.02 to $50.01, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.02 to $50.67, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F5

The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.05 to $50.03, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F6

The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.13 to $50.78, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F7

The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.88, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)